Publication:
HLA class I and class II antigens in Turkish patients with chronic ordinary urticaria

dc.contributor.buuauthorAydoğan, Kenan
dc.contributor.buuauthorKaradoğan, Serap Köran
dc.contributor.buuauthorAkdağ, İhsan Ömür
dc.contributor.buuauthorTunalı, Şükran
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDermatoloji Ana Bilim Dalı
dc.contributor.departmentNefroloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-0193-1128
dc.contributor.researcheridAAH-6216-2021
dc.contributor.scopusid9739755800
dc.contributor.scopusid9738885800
dc.contributor.scopusid8342488100
dc.contributor.scopusid7004191748
dc.date.accessioned2021-10-08T07:30:26Z
dc.date.available2021-10-08T07:30:26Z
dc.date.issued2006
dc.description.abstractBackground. Chronic urticaria is a common disease with an unclear pathogenesis, which may be resistant to therapy. Recent studies have focused primarily on a possible autoimmune basis. Aim. To investigate HLA class I and II antigens in a Turkish population with chronic ordinary urticaria (COU; not physical, vasculitic or contact), and identify susceptible HLA antigens. Methods. HLA antigens were investigated in 55 patients diagnosed with COU, using a two-stage microdroplet lymphocytotoxicity test, with 104 healthy and genetically unrelated individuals evaluated as the control group. Results. HLA Bw4 and HLA DQ1 antigens were significantly higher in the study group (odds ratio (OR) = 2.93, 95% CI 1.47-5.85, P = 0.003 and OR = 7.81, 95% CI 1.96-28.50, P = 0.001, respectively) whereas HLA-A24 antigen was higher in controls (OR = 0.36, 95% CI 0.15-0.86, P = 0.03). Conclusion. We propose that HLA-Bw4 and DQ1 antigens may be responsible for susceptibility to COU while HLA-A24 may have a protective role in the Turkish population.
dc.identifier.citationAydoğan, K. vd. (2006). ''HLA class I and class II antigens in Turkish patients with chronic ordinary urticaria''. Clinical and Experimental Dermatology, 31(3), 424-429.
dc.identifier.endpage429
dc.identifier.issn0307-6938
dc.identifier.issn1365-2230
dc.identifier.issue3
dc.identifier.pubmed16681593
dc.identifier.scopus2-s2.0-33645420708
dc.identifier.startpage424
dc.identifier.urihttps://doi.org/10.1111/j.1365-2230.2005.02039.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1365-2230.2005.02039.x
dc.identifier.urihttp://hdl.handle.net/11452/22296
dc.identifier.volume31
dc.identifier.wos000236242400025
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherDermatology
dc.relation.journalClinical and Experimental Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDermatology
dc.subjectEdema
dc.subjectLinkage
dc.subjectAssociation
dc.subject.emtreeHLA DQ1 antigen
dc.subject.emtreeHLA B antigen
dc.subject.emtreeHLA antigen class 2
dc.subject.emtreeHLA antigen class 1
dc.subject.emtreeHLA antigen
dc.subject.emtreeHLA A24 antigen
dc.subject.meshUrticaria
dc.subject.meshTurkey
dc.subject.meshMiddle aged
dc.subject.meshMale
dc.subject.meshLogistic models
dc.subject.meshHumans
dc.subject.meshHLA-DQ antigens
dc.subject.meshHLA-B antigens
dc.subject.meshHLA-A antigens
dc.subject.meshHLA antigens
dc.subject.meshFluorescent antibody technique
dc.subject.meshFemale
dc.subject.meshDisease susceptibility
dc.subject.meshCytotoxicity tests, immunologic
dc.subject.meshChronic disease
dc.subject.meshChi-square distribution
dc.subject.meshCase-control studies
dc.subject.meshAged
dc.subject.meshAdult
dc.subject.scopusOmalizumab; Urticaria; Non-Sedating Histamine H1 Antagonists
dc.subject.wosDermatology
dc.titleHLA class I and class II antigens in Turkish patients with chronic ordinary urticaria
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dermatoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Nefroloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: